Shilpa Gupta, Director of Genitourinary Oncology at the Cleveland Clinic, shared Yüksel Ürün’s, Professor of Medical Oncology at Ankara University School of Medicine, post on X, adding:
“Thanks for the shout out Yüksel Ürün.
Delighted to share our latest review in Journal of Clinical Oncology Practice on Current Evidence and Practice Considerations of ADCs in UC, in a truly explosive novel ADC era.
Congrats Samer Salem, Kainat Warraich on leading this work.”
Quoting Yüksel Ürün’s post:
“EV+pembrolizumab displaced platinum in 1L urothelial cancer.
But resistance, toxicity and sequencing remain unresolved. The next gains may come from biomarkers, smarter dosing and de-escalation.”
Title: Antibody Drug Conjugates in Urothelial Carcinoma: Current Evidence and Practice Considerations
Authors: Samer Salem, Kainat Warraich, Shilpa Gupta.
You can also read ‘RADICAL Trial: Radium-223 Plus Cabozantinib Does Not Improve SSE-FS in mRCC With Bone Metastases‘
